Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model

Podobne zapisy

• No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
  od: Viviana Laredo, i wsp.
  Wydane: (2020-05-01)
• No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
  od: Laredo, Viviana, i wsp.
  Wydane: (2020)
• Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
  od: I. N. Dyakov, i wsp.
  Wydane: (2020-09-01)
• Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor?
  od: Biondi-Zoccai, Giuseppe, i wsp.
  Wydane: (2010)
• The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
  od: Choi, Woong Gil, i wsp.
  Wydane: (2021)